Follow-up samples with cytogenetic and PB plasma LOH analysis
Patient . | Diagnosis* . | % BM blasts . | % positive metaphases† . | Plasma LOH . |
|---|---|---|---|---|
| 1 | RAEB-T | 54 | 73.3 | L |
| 2 | RAEB-T | 26 | 100 | L |
| 3 | RAEB | 12 | 100 | L |
| 4 | RAEB | 0 | 5 | L |
| 5 | RAEB | 3 | 10 | N |
| 6 | RA | 1 | 28.6 | L |
| 7 | RAEB | 2 | 100 | L |
| 8 | RAEB | 70 | 100 | L |
| 9 | RAEB | 0 | 0 | N |
| 10 | RAEB-T | 5 | 100 | L |
| 11 | AML | 2 | 0 | N |
| 12 | AML | 29 | 10 | L |
| 13 | AML | 5 | 0 | N |
| 14 | AML | 0 | 0 | N |
| 15 | AML | 7 | 0 | N |
| 16 | AML | 1 | 0 | N |
Patient . | Diagnosis* . | % BM blasts . | % positive metaphases† . | Plasma LOH . |
|---|---|---|---|---|
| 1 | RAEB-T | 54 | 73.3 | L |
| 2 | RAEB-T | 26 | 100 | L |
| 3 | RAEB | 12 | 100 | L |
| 4 | RAEB | 0 | 5 | L |
| 5 | RAEB | 3 | 10 | N |
| 6 | RA | 1 | 28.6 | L |
| 7 | RAEB | 2 | 100 | L |
| 8 | RAEB | 70 | 100 | L |
| 9 | RAEB | 0 | 0 | N |
| 10 | RAEB-T | 5 | 100 | L |
| 11 | AML | 2 | 0 | N |
| 12 | AML | 29 | 10 | L |
| 13 | AML | 5 | 0 | N |
| 14 | AML | 0 | 0 | N |
| 15 | AML | 7 | 0 | N |
| 16 | AML | 1 | 0 | N |
BM indicates bone marrow; LOH, loss of heterozygosity; RAEB-T, refractory anemia with excess of blasts transformed; RAEB, refractory anemia with excess of blasts; RA, refractory anemia; AML, acute myeloid leukemia; L, loss of heterozygosity; N, normal pattern.
Diagnosis is based on the bone marrow findings at the time of presentation.
The percentage of abnormal metaphases is based on analyzing 20 metaphases.